A comparative study of chronic kidney disease in dogs and cats: Induction of cyclooxygenases

Research in Veterinary Science

Volumn 93, Issue 2, 2012, Pages 892-897

  Yabuki, Akira ^a   Mitani, Sawane ^a   Sawa, Mariko ^a   Mizukami, Keijiro ^a   Fujiki, Makoto ^a   Yamato, Osamu ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cats; Chronic kidney disease; COX 1; COX 2; Dogs

Indexed keywords

CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE;

ANIMAL TISSUE; ARTICLE; CAT; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DOG; GLOMERULOSCLEROSIS; GLOMERULUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY FIBROSIS; MACULA DENSA; NONHUMAN; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS;

ANIMALS; CAT DISEASES; CATS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOG DISEASES; DOGS; ENZYME INDUCTION; RENAL INSUFFICIENCY, CHRONIC;

CANIS FAMILIARIS; FELIDAE;

EID: 84863100554     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.12.017     Document Type: Article

References (29)

1. Câmpean V., Theilig F., Paliege A., Breyer M., Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). American Journal of Physiology Renal Physiology 2003, 285:F19-32.
2. Cheng H.F., Wang C.J., Moeckel G.W., Zhang M.Z., McKanna J.A., Harris R.C. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney International 2002, 62:929-939.
3. Craven P.A., Patterson M.C., DeRubertis F.R. Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats. Diabetes 1988, 37:429-435.
4. Doré M. Cyclooxygenase-2 expression in animal cancers. Veterinary Pathology 2011, 48:254-265.
5. Fujihara C.K., Antunes G.R., Mattar A.L., Andreoli N., Malheiros D.M., Noronha I.L., Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney International 2003, 64:2172-2181.
6. Grauter G.F. Acute renal failure and chronic kidney disease. Small Animal Internal Medicine 2009, 645-659. Mosby, Missouri. fourth ed. R.W. Nelson, C.G. Couto (Eds.).
7. Harris R.C. Cyclooxygenase-2 inhibition and renal physiology. American Journal of Cardiology 2002, 89:10D-17D.
8. Harris R.C., Breyer M.D. Physiological regulation of cyclooxygenase-2 in the kidney. American Journal of Physiology Renal Physiology 2001, 281:F1-F11.
9. Hartner A., Pahl A., Brune K., Goppelt-Struebe M. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis. Inflammation Research 2000, 49:345-354.
10. Hirose S., Yamamoto T., Feng L., Yaoita E., Kawasaki K., Goto S., Fujinaka H., Wilson C.B., Arakawa M., Kihara I. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. Journal of the American Society of Nephrology 1998, 9:408-416.
11. Hao C.M., Breyer M.D. Physiological regulation of prostaglandins in the kidney. Annual Review of Physiology 2008, 70:357-377.
12. Kawaguchi H., Saito H., Yasuda H. Renal prostaglandins and phospholipase A2 in spontaneously hypertensive rats. Journal of Hypertension 1987, 5:299-304.
13. Khan K.N., Stanfield K.M., Harris R.K., Baron D.A. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Failure 2001, 23:321-330.
14. Khan K.N., Venturini C.M., Bunch R.T., Brassard J.A., Koki A.T., Morris D.L., Trump B.F., Maziasz T.J., Alden C.L. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicologic Pathology 1998, 26:612-620.
15. Komers R., Lindsley J.N., Oyama T.T., Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clinical and Experimental Pharmacology and Physiology 2007, 34:36-41.
16. Kuo H.W., Tsai S.S., Tiao M.M., Liu Y.C., Lee I.M., Yang C.Y. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiology and Drug Safety 2010, 19:745-751.
17. Lianos E.A., Andres G.A., Dunn M.J. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis Effects on renal hemodynamics. The Journal of Clinical Investigation 1983, 72:1439-1448.
18. Miyajima A., Ito K., Asano T., Seta K., Ueda A., Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction?. The Journal of Urology 2001, 166:1124-1129.
19. Nørregaard R., Jensen B.L., Topcu S.O., Wang G., Schweer H., Nielsen S., Frøkiaer J. Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue. American Journal of Physiology Regulation Integration and Comparative Physiology 2010, 298:R1017-1025.
20. Okamoto T., Hino O. Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. International Journal of Molecular Medicine 2000, 6:455-457.
21. Raij L., Azar S., Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney International 1984, 26:137-143.
22. Rakusan D., Kujal P., Kramer H.J., Husková Z., Vanourková Z., Vernerová Z., Mrázová I., Thumová M., Cervenka L., Vanecková I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. American Journal of Physiology Renal Physiology 2010, 299:F758-766.
23. Solari V., Piotrowska A.P., Cascio S., Unemoto K., Chertin B., Puri P. Cyclooxygenase-2 up-regulation in reflux nephropathy. The Journal of Urology 2003, 170:1624-1627.
24. Sraer J.D., Moulonguet-Doleris L., Delarue F., Sraer J., Ardaillou R. Prostaglandin synthesis by glomeruli isolated from rats with glycerol-induced acute renal failure. Circulation Research 1981, 49:775-783.
25. Tomasoni S., Noris M., Zappella S., Gotti E., Casiraghi F., Bonazzola S., Benigni A., Remuzzi G. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. Journal of the American Society of Nephrology 1998, 9:1202-1212.
26. Yabuki A., Mitani S., Fujiki M., Misumi K., Endo Y., Miyoshi N., Yamato O. Comparative study of chronic kidney disease in dogs and cats: induction of myofibroblasts. Research in Veterinary Science 2010, 88:249-294.
27. Yabuki A., Suzuki S., Matsumoto M., Nishinakagawa H. Morphometrical analysis of sex and strain differences in the mouse nephron. The Journal of Veterinary Medical Science 1999, 61:891-896.
28. Yamamoto E., Izawa T., Juniantito V., Kuwamura M., Sugiura K., Takeuchi T., Yamate J. Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. Histology and Histopathology 2010, 25:995-1007.
29. Vogt L., de Zeeuw D., Woittiez A.J., Navis G. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrology and Dialysis Transplantation 2009, 24:1182-1189.